EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Akebia Therapeutics's Enterprise Value is $248.2 Mil.
Akebia Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-25.3 Mil. Therefore, Akebia Therapeutics's EV-to-FCF for today is -9.82.
The historical rank and industry rank for Akebia Therapeutics's EV-to-FCF or its related term are showing as below:
AKBA'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.85 Med: -1.78 Max: 13.66
Current: -9.82
During the past 12 years, the highest EV-to-FCF of Akebia Therapeutics was 13.66. The lowest was -17.85. And the median was -1.78.
AKBA's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.56
vs AKBA: -9.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Akebia Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akebia Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Akebia Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's EV-to-FCF falls into.
Akebia Therapeutics's current Enterprise Value is $248.2 Mil.
Akebia Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Akebia Therapeutics's PE Ratio for today is calculated as:
Akebia Therapeutics's share price for today is $1.14.
Akebia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.227.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Akebia Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics (Akebia Therapeutics) Business Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKBA has been successfully added to your 